"The U.S. Food and Drug Administration approved the ResQCPR System, a system of two devices for first responders to use while performing cardiopulmonary resuscitation (CPR) on people whose hearts stop beating (cardiac arrest). The devices may impr"...
Clinical Trials Experience
The following serious adverse reactions are also discussed elsewhere in the labeling:
- Bleeding [see BOXED WARNING and WARNINGS AND PRECAUTIONS]
- Thrombotic thrombocytopenic purpura [see WARNINGS AND PRECAUTIONS]
Safety in patients with ACS undergoing PCI was evaluated in a clopidogrel-controlled study, TRITON-TIMI 38, in which 6741 patients were treated with Effient (60-mg loading dose and 10-mg once daily) for a median of 14.5 months (5802 patients were treated for over 6 months; 4136 patients were treated for more than 1 year). The population treated with Effient was 27 to 96 years of age, 25% female, and 92% Caucasian. All patients in the TRITON-TIMI 38 study were to receive aspirin. The dose of clopidogrel in this study was a 300-mg loading dose and 75-mg once daily.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials cannot be directly compared with the rates observed in other clinical trials of another drug and may not reflect the rates observed in practice.
The rate of study drug discontinuation because of adverse reactions was 7.2% for Effient and 6.3% for clopidogrel. Bleeding was the most common adverse reaction leading to study drug discontinuation for both drugs (2.5% for Effient and 1.4% for clopidogrel).
Bleeding Unrelated to CABG Surgery - In TRITON-TIMI 38, overall rates of TIMI Major or Minor bleeding adverse reactions unrelated to coronary artery bypass graft surgery (CABG) were significantly higher on Effient than on clopidogrel, as shown in Table 1.
Table 1: Non-CABG-Related Bleedinga(TRITON-TIMI 38)
|TIMI Major or Minor bleeding||4.5||3.4|
|TIMI Major bleedingb||2.2||1.7|
|Symptomatic intracranial hemorrhage (ICH)||0.3||0.3|
|Requiring surgical intervention||0.3||0.3|
|Requiring transfusion ( ≥ 4 units)||0.7||0.5|
|TIMI Minor bleedingb||2.4||1.9|
|aPatients may be counted in more than one row.
bSee for definition.
Figure 1 demonstrates non-CABG related TIMI Major or Minor bleeding. The bleeding rate is highest initially, as shown in Figure 1 (inset: Days 0 to 7) [see WARNINGS AND PRECAUTIONS].
Bleeding by Weight and Age
In TRITON-TIMI 38, non-CABG-related TIMI Major or Minor bleeding rates in patients with the risk factors of age ≥ 75 years and weight < 60 kg are shown in Table 2.
Table 2: Bleeding Rates for
Non-CABG-Related Bleeding by Weight and Age (TRITON-TIMI 38)
|Effienta (%)||Clopidogrelb (%)||Effienta (%)||Clopidogrelb (%)|
|Weight < 60 kg (N=308 Effient, N=356 clopidogrel)||10.1||6.5||0.0||0.3|
|Weight ≥ 60 kg (N=6373 Effient, N=6299 clopidogrel)||4.2||3.3||0.3||0.1|
|Age < 75 years (N=5850 Effient, N=5822 clopidogrel)||3.8||2.9||0.2||0.1|
|Age ≥ 75 years (N=891 Effient, N=894 clopidogrel)||9.0||6.9||1.0||0.1|
|a10-mg Effient maintenance dose
b75-mg clopidogrel maintenance dose
Bleeding Related to CABG
In TRITON-TIMI 38, 437 patients who received a thienopyridine underwent CABG during the course of the study. The rate of CABG-related TIMI Major or Minor bleeding was 14.1% for the Effient group and 4.5% in the clopidogrel group (see Table 3). The higher risk for bleeding adverse reactions in patients treated with Effient persisted up to 7 days from the most recent dose of study drug.
Table 3: CABG-Related
Bleedinga (TRITON-TIMI 38)
|TIMI Major or Minor bleeding||14.1||4.5|
|TIMI Major bleeding||11.3||3.6|
|Transfusion of ≥ 5 units||6.6||2.2|
|TIMI Minor bleeding||2.8||0.9|
|a Patients may be counted in more than one row.|
Bleeding Reported as Adverse Reactions - Hemorrhagic events reported as adverse reactions in TRITON-TIMI 38 were, for Effient and clopidogrel, respectively: epistaxis (6.2%, 3.3%), gastrointestinal hemorrhage (1.5%, 1.0%), hemoptysis (0.6%, 0.5%), subcutaneous hematoma (0.5%, 0.2%), post-procedural hemorrhage (0.5%, 0.2%), retroperitoneal hemorrhage (0.3%, 0.2%), pericardial effusion/hemorrhage/tamponade (0.3%, 0.2%), and retinal hemorrhage (0.0%, 0.1%).
During TRITON-TIMI 38, newly-diagnosed malignancies were reported in 1.6% and 1.2% of patients treated with prasugrel and clopidogrel, respectively. The sites contributing to the differences were primarily colon and lung. In another Phase 3 clinical study of ACS patients not undergoing PCI, in which data for malignancies were prospectively collected, newly-diagnosed malignancies were reported in 1.8% and 1.7% of patients treated with prasugrel and clopidogrel, respectively. The site of malignancies was balanced between treatment groups except for colorectal malignancies. The rates of colorectal malignancies were 0.3% prasugrel, 0.1% clopidogrel and most were detected during investigation of GI bleed or anemia. It is unclear if these observations are causally-related, are the result of increased detection because of bleeding, or are random occurrences. Other Adverse Events
In TRITON-TIMI 38, common and other important non-hemorrhagic adverse events were, for Effient and clopidogrel, respectively: severe thrombocytopenia (0.06%, 0.04%), anemia (2.2%, 2.0%), abnormal hepatic function (0.22%, 0.27%), allergic reactions (0.36%, 0.36%), and angioedema (0.06%, 0.04%). Table 4 summarizes the adverse events reported by at least 2.5% of patients.
Table 4: Non-Hemorrhagic Treatment Emergent Adverse
Events Reported by at Least 2.5% of Patients in Either Group
|Effient (%) (N=6741)||Clopidogrel (%) (N=6716)|
|Non-cardiac chest pain||3.1||3.5|
|Leukopenia ( < 4 x 109 WBC/L)||2.8||3.5|
|Pain in extremity||2.6||2.6|
The following adverse reactions have been identified during post approval use of Effient. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Read the Effient (prasugrel tablets) Side Effects Center for a complete guide to possible side effects
Non-Steroidal Anti-Inflammatory Drugs
Other Concomitant Medications
Effient can be administered with drugs that are inducers or inhibitors of cytochrome P450 enzymes [see CLINICAL PHARMACOLOGY].
Effient can be administered with aspirin (75-mg to 325-mg per day), heparin, GPIIb/IIIa inhibitors, statins, digoxin, and drugs that elevate gastric pH, including proton pump inhibitors and H2 blockers [see CLINICAL PHARMACOLOGY].
Read the Effient Drug Interactions Center for a complete guide to possible interactions
Last reviewed on RxList: 7/29/2015
Additional Effient Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.